Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP: Preoperative Elacestrant and PULSAR in Breast Cancer
NCT07005882Phase 2Not yet recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Azienda Ospedaliero-Universitaria Careggi. Primary endpoint: Safety of Elacestrant combined with PULSAR radiation therapy in preoperative setting. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07005882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005882.